1.3…75.3 mPa |
ENaC overexpressing Oocytes |
Activated Epithelial Na+ Channels (ENaC) |
[35] |
20…400 mPa |
Vascular endothelial cells |
Modulated cytosolic-free calcium |
[36] |
20…17000 mPa |
Endothelial cell |
Activated K+ current |
[37] |
60…1500 mPa |
Aortic endothelial cells |
Modulated expression of Cu/Zn superoxide dismutase |
[38] |
100…1500 mPa |
Aortic endothelial cells |
Increases in pinocytotic rate |
[39] |
120…1500 mPa |
Endothelial cell |
Induction of ecNOS mRNA in a dose-dependent manner |
[40] |
150…1000 mPa |
Embryonic stem cells |
Increased the expression of vascular endothelial cell-specific markers at the protein level and the mRNA level |
[41] |
160, 410, 820 mPa and 1.64 Pa |
Chondrocytes |
Upregulated nitric oxide, membrane phosphatidylserine and nucleosomal degradation |
[42] |
200 mPa |
Arterial vascular endothelial cells |
Induction of endothelial stress fibers |
[43] |
350…11700 mPa |
Endothelial cells |
Stimulated mitogen-activated protein kinase |
[44] |
500…1000 mPa |
Aortic endothelial cells |
Changes in cell morphology |
[45] |
500…2500 Pa |
Aortic smooth muscle cells |
Reduced proliferation rate |
[46] |
600…2500 mPa |
Endothelial cells |
Induced nitric oxide production |
[47] |
600…2600 mPa |
Endothelial cells |
Reorganization of the cytoskeleton |
[48] |
800…1500 mPa |
Vascular endothelial cell |
Cell alignment in the direction of flow without initiating the cell cycle |
[49] |
1 Pa |
Osteoblasts |
Induced β-catenin signaling |
[50] |
1…2 Pa |
Smooth muscle cell |
Inhibited migration |
[51] |
1, 2 Pa |
Osteoblastic cells |
Produced higher magnitude and more abundant [Ca2+]i-oscillations than spontaneously |
[52] |
1, 3, 8.5 Pa |
Endothelial cells |
Shape change and cytoskeleton reorganization |
[53] |
1…8.5 Pa |
Vascular endothelial cells |
Orientation with the flow direction |
[54] |
1.2 Pa |
Endothelial cells |
Reorganization of the surface topography |
[55, 56] |
1.2 Pa |
Vascular endothelial cells |
Enhanced activation of transcription factors |
[57] |
1.5 Pa |
Venous endothelial cells |
Stimulated phosphorylation of Akt |
[58] |
1.52 Pa |
Endothelial cells |
Reorganization of the cytoskeleton |
[59] |
1.6 Pa |
Chondrocytes |
Down-regulation of the aggrecan gene expression |
[60] |
1.6 Pa |
Chondrocytes |
Stimulated glycosaminoglycan synthesis |
[61] |
1.64 Pa |
Chondrocytes |
Upregulated NO synthase gene expression and increased NO release; inhibited type II collagen and aggrecan mRNA levels |
[62] |
1.7…2.0 Pa |
Osteoblast-like SaOS-2 cells |
Increased TGF-β1 mRNA expression |
[63] |
2 Pa |
Endothelial cells |
Shape change and cytoskeletal remodeling |
[64] |
2 Pa |
Osteoblast |
Increased proliferation |
[65] |
3.5 Pa |
Chondrocytes |
Promoted chondrocyte proliferation |
[66] |